Roche Holding AG (OTCMKTS:RHHBY) Shares Sold by Beach Investment Counsel Inc. PA

Beach Investment Counsel Inc. PA decreased its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,560 shares of the company’s stock after selling 12,380 shares during the quarter. Beach Investment Counsel Inc. PA’s holdings in Roche were worth $2,008,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Brooklyn Investment Group purchased a new stake in shares of Roche in the third quarter valued at approximately $40,000. AlphaMark Advisors LLC purchased a new position in Roche in the third quarter worth approximately $149,000. IHT Wealth Management LLC purchased a new position in Roche in the third quarter worth approximately $236,000. Verity Asset Management Inc. purchased a new position in Roche in the third quarter worth approximately $253,000. Finally, Canopy Partners LLC grew its position in Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after acquiring an additional 344 shares during the period.

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein upgraded Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a sell rating, one has given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Roche currently has a consensus rating of “Hold”.

Roche Stock Up 0.2 %

RHHBY opened at $39.32 on Tuesday. Roche Holding AG has a 52 week low of $29.20 and a 52 week high of $42.43. The business has a fifty day simple moving average of $36.22 and a 200-day simple moving average of $38.28. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.